Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab biosimilars have been keenly awaited since, and were first launched in the … More Biosimilars in Oncology: Trastuzumab is taking off
Mark Morrison, who joins as COO, was previously with Novartis and had global and regional leadership roles based in Switzerland (Basel) and Indonesia (Jakarta). As a Global Brand Director Mark led global launches for Cardiovascular and Respiratory innovative pharmaceuticals. Within the Asia – Middle East – Africa region Mark was Franchise Head for the Primary … More Global Pricing Innovations (GPI) adds experienced, global Pharma Industry executive as Chief Operating Officer (COO) and senior pricing expert to lead pricing and consultancy.
Partners4Access (P4A), the orphan drug specialists, and Global Pricing Innovations (GPI), the pricing experts, are moving to larger premises in central London to account for expansion and growth. Aligned to their innovative thinking and approach with their pharmaceutical clients, the new premises are designed to be a space that inspires and energises their employees. Schmitz, … More Partners4Access and Global Pricing Innovations open new London Headquarters to complement innovative thinking and disruptive technology growth
Global Pricing Innovations (GPI) has further strengthened its technology division with the addition of Mikhael Aktsyzniy Mikhael joins GPI from Accenture as Head of Technology and Development to continue GPI’s success providing powerful pharma pricing intelligence based business services to valued clients across Europe and the US. He will be based at the firm’s Global … More Pharma Pricing Experts, Global Pricing Innovation, Announce the Appointment of Mikhael Aktsyzniy to Head Technology and Development
Canada’s plan to revise reference basket In a bid to reduce medicine prices in Canada, the Canadian Minister of Health announced the revision of the reference basket for international reference pricing (IRP). Medicines prices in Canada are regulated by the federal government, through the PMPRB (Patented Medicine Prices Review Board). The current reference rule used … More International Reference Pricing Reforms
With the largest population in the Middle East and North Africa region, Egypt has attracted a strong presence from multinational pharmaceutical companies. However, current turmoil over drug shortages and drug price hikes underscores the volatility of a market characterised by high out-of-pocket spending. Amid the economic instability that followed the 2011 Arab Spring, President Abdel-Fattah … More Egypt: Drug Price Hikes Highlight Market Volatility